Clinical Trial Update: The Efficacy of Hepatic Arterial Infusion Chemotherapy (HAIC) Combine Lenvatinib and Durvalumab (HILL) in Advanced Hepatocellular Carcinoma (HCC) [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating hepatic arterial infusion chemotherapy combined with lenvatinib and durvalumab for advanced hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Durvalumab (durvalumab)
• Hepatic Arterial Infusion Chemotherapy
• Lenvatinib (lenvatinib)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: UNKNOWN